BioWorld Asia

Oct. 4, 2006

ProStrakan's Agreement With Novartis Could Reach $140M

LONDON - ProStrakan Group plc sealed a deal with a headline value of $140 million under which Novartis AG will develop antibody treatments for bone-related diseases using a ProStrakan target. (BioWorld International) Read More

Crucell Pays Acambis $16.5M To Obtain Vivotif's U.S. Rights

Study: Alzheimer's Protein Has Role In Cell Signalling

EU Pharmaceutical Forum Calls For Research Support

RNAi Deal Involves Quark, Pfizer, Atugen, SR Pharma

Roslin Institute Forms Facility For Producing Stem Cell Lines

Pharmaxon's Seed Financing For Nervous System Diseases

Gamida Cell Raises $16M To Broaden Its Programs

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 29, 2026.

Illustration for mutations in the DNA leading to brain diseases or neurodegenerative disorders

ENCALS 2026: From genetics to advancing strategies against ALS

BioWorld Science

Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...

Next wave of BCI firms builds on pioneers to tackle challenges

BioWorld

With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...

Boehringer Ingelheim identifies new mGlu3 receptor agonists

BioWorld Science

Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...

GT-02897 exerts efficacy in preclinical multiple myeloma

BioWorld Science

Investigators from the Karl Landsteiner University aimed to evaluate the therapeutic potential of a novel CDK9 inhibitor/degrader, GT-02897, for the potential...